摘要
狂犬病是一种重要的人兽共患传染病,每年全世界约有上百万人暴露于该病。狂犬病严重暴露者应在接种狂犬病疫苗进行主动免疫的同时,接种马抗狂犬病病毒免疫球蛋白(ERIG)或人抗狂犬病病毒免疫球蛋白(HRIG)进行被动免疫。然而,应用ERIG或HRIG存在引起过敏反应或传播血液性疾病的危险,应用治疗性单克隆抗体可以克服上述缺点。本文就鼠源性狂犬病病毒单克隆抗体和人源化狂犬病病毒单克隆抗体的研究进展、作用机制及大规模研制等作一综述。
Rabies is an important zoonosis that results in millions of human exposures worldwide every year.In combination with vaccine,passive immunization is an important parameter of post-exposure rabies prophylaxis.Two types of rabies immunoglobulin（RIG）,i.e.human rabies immunoglobulin（HRIG）and equine rabies immunoglobulin（ERIG）,are currently available for passive immunization against rabies.However,the passive immunization with HRIG or ERIG is at a potential risk of anaphylaxis or blood-borne infectious diseases,which may be overcome by therapeutic monoclonal antibody（McAb）.The progress in research,action mechanism and large-scale preparation of therapeutic McAbs against rabies virus from mouse and human origins are reviewed in this paper.
出处
《中国生物制品学杂志》
CAS
CSCD
2009年第10期1032-1035,共4页
Chinese Journal of Biologicals
